Skip to main content

Advertisement

Table 2 Cox regression analysis for all LUAD patients

From: Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients

Covariates A. K-Ras4A expression Covariates B. K-Ras4A proportion
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HRa
(95% CIb)
p-value HR
(95% CI)
p-value HR
(95% CI)
p-value HR
(95% CI)
p-value
Age (≥65 years) 1.154 (0.857−1.553) 0.346 1.198 (0.879−1.632) 0.253 Age (≥65 years) 1.154 (0.857−1.553) 0.346 1.206 (0.885−1.643) 0.236
Gender (Male) 1.063 (0.797−1.417) 0.678 1.190 (0.871−1.625) 0.274 Gender (Male) 1.063 (0.797−1.417) 0.678 1.185 (0.867−1.619) 0.287
Smoking history 1.019 (0.887−1.170) 0.790 1.038 (0.895−1.202) 0.625 Smoking history 1.019 (0.887−1.170) 0.790 1.039 (0.896−1.204) 0.615
K-Ras4A expression (low) 0.766 (0.573−1.023) 0.0705 0.900 (0.644−1.257) 0.537 K-Ras4A proportion (low) 0.952 (0.714−1.268) 0.735 1.049 (0.762−1.444) 0.770
KRAS amplification (Not amplified) 0.580 (0.382−0.880) 0.0104 0.623 (0.395−0.983) 0.0421 KRAS amplification (Not amplified) 0.580 (0.382−0.880) 0.0104 0.619 (0.393−0.977) 0.0393
KRAS mutations (Present) 1.194 (0.867−1.643) 0.277 1.246 (0.856−1.813) 0.252 KRAS mutations (Present) 1.194 (0.867−1.643) 0.277 1.319 (0.915−1.901) 0.138
EGFR mutations (Present) 1.322 (0.831−2.104) 0.239 1.460 (0.869−2.454) 0.153 EGFR mutations (Present) 1.322 (0.831−2.104) 0.239 1.436 (0.855−2.412) 0.172
Pathological stage (III/IV) 2.635 (1.939−3.581) 5.94E-10 2.486 (1.796−3.443) 4.14E-8 Pathological stage (III/IV) 2.635 (1.939−3.581) 5.94E-10 2.513 (1.815−3.480) 2.90E-8
  1. aHR, hazard ratio
  2. bCI, confidence interval